Tech transfer offices are under increasing pressure to generate revenue, but an innovative tech transfer strategy can help them deliver.
Tech transfer offices are still defined by major licensing blockbusters – for example Northwestern’s royalties from epilepsy drug Lyrica or Columbia’s Axel patents, which cover a method of introducing foreign proteins into nucleated cells – but the field is taking on new dimensions as universities increasingly see those offices as critical revenue drivers. As a…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
